Ticker >

Caplin Point Lab share price

Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT BSE: 524742 SECTOR: Pharmaceuticals & Drugs  169k   1k   216

1291.55
-23.25 (-1.77%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1315

Today's Low

₹ 1285.3

52 Week High

₹ 1617.8

52 Week Low

₹ 711.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

9808.26 Cr.

Enterprise Value

9536.88 Cr.

No. of Shares

7.59 Cr.

P/E

34.57

P/B

7.06

Face Value

₹ 2

Div. Yield

0.19 %

Book Value (TTM)

₹  183.05

CASH

271.38 Cr.

DEBT

0 Cr.

Promoter Holding

70.62 %

EPS (TTM)

₹  37.36

Sales Growth

0.1%

ROE

22.97 %

ROCE

28.33%

Profit Growth

24.69 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year0.1%
3 Year0.05%
5 Year4.38%

Profit Growth

1 Year24.69%
3 Year5.83%
5 Year18.02%

ROE%

1 Year22.97%
3 Year23.01%
5 Year29.85%

ROCE %

1 Year28.33%
3 Year29.63%
5 Year38.74%

Debt/Equity

0

Price to Cash Flow

62.43

Interest Cover Ratio

2443.91666666667

CFO/PAT (5 Yr. Avg.)

0.949029881027739

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 70.62 0
Dec 2023 70.62 0
Sep 2023 70.63 0
Jun 2023 70.63 0
Mar 2023 70.66 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 23.0112803043094% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.6322511625731% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 2443.91666666667.
  • The Company has been maintaining an effective average operating margins of 40.1638843767566% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -53.3505090417708 days.
  • Company has a healthy liquidity position with current ratio of 4.52148450800136.
  • The company has a high promoter holding of 70.62%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 56.1366761658211.

 Limitations

  • The company has shown a poor profit growth of 5.83001636474549% for the Past 3 years.
  • The company has shown a poor revenue growth of 0.0495305052316208% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 144.67 173.66 179.22 132.83 139.38
Total Expenditure 79.8 97.04 89.77 69.51 81.7
Operating Profit 64.87 76.62 89.45 63.32 57.68
Other Income 12.22 27.27 24.49 17.9 36.18
Interest 0.03 0.03 0.02 0.03 0.02
Depreciation 6.29 6.67 6.72 6.76 6.93
Exceptional Items 0 0 0 0 0
Profit Before Tax 70.77 97.19 107.2 74.43 86.91
Tax 16.44 20.92 25.1 18.98 17.03
Profit After Tax 54.33 76.27 82.1 55.45 69.88
Adjusted EPS (Rs) 7.16 10.04 10.81 7.3 9.2

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 536.91 527.83 482.68 528.06 528.61
Total Expenditure 348.31 320.83 273.14 308.58 309.23
Operating Profit 188.6 206.99 209.54 219.48 219.38
Other Income 35.4 65.97 23.01 56.69 99.54
Interest 0.5 0.19 0.17 0.09 0.12
Depreciation 20.84 19.65 22.44 25.77 25.65
Exceptional Items 0 0 0 0 0
Profit Before Tax 202.65 253.12 209.94 250.31 293.15
Tax 54.49 55.49 53.71 62.44 58.89
Net Profit 148.17 197.64 156.23 187.87 234.26
Adjusted EPS (Rs.) 19.59 26.13 20.65 24.79 30.86

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 15.13 15.13 15.13 15.16 15.18
Total Reserves 416.92 584.78 743.54 915.49 1124.73
Borrowings 0.29 0.02 0 0 0
Other N/C liabilities 24.48 27.15 24.99 24.63 16.42
Current liabilities 82.51 64.26 77.33 98.88 146.85
Total Liabilities 539.33 691.33 860.99 1054.16 1303.18
Assets
Net Block 137.77 166.93 182.68 162.46 156.85
Capital WIP 8.62 3.77 1.36 1.73 42.68
Intangible WIP 0 0 0 0.87 0
Investments 98.62 135.54 138.64 212.73 274.97
Loans & Advances 6.36 4.36 5.67 70.7 164.7
Other N/C Assets 0 0 20 0 0
Current Assets 287.95 380.74 512.64 605.67 663.98
Total Assets 539.33 691.33 860.99 1054.16 1303.18
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 202.65 253.12 209.94 250.31 293.15
Adjustment -0.29 -32.58 7.75 -19.43 -59.57
Changes in Assets & Liabilities -54.17 -83.19 131.85 62.07 -11.45
Tax Paid -40.84 -50.35 -54.9 -61.98 -65.03
Operating Cash Flow 107.34 87.01 294.64 230.97 157.1
Investing Cash Flow -75.79 -41 -3.9 -276.02 -85.67
Financing Cash Flow -15.21 -32.92 -3.47 -22.76 -30.42
Net Cash Flow 16.34 13.09 287.27 -67.81 41.01

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 70.66 70.63 70.63 70.62 70.62
ashok gorkey partheeban 11.92 11.92 11.92 11.92 11.92
first dimension holdings ... 0.49 0.49 0.49 0.49 0.49
kiraviz properties and co... 0.20 0.20 0.20 0.20 0.20
may india property privat... 2.79 2.79 2.79 2.79 2.79
p vijayalakshmi 24.74 24.73 24.73 24.73 24.73
paarthipan c c 18.66 18.66 18.66 18.66 18.66
partheeban vivek siddarth... 11.86 11.85 11.85 11.85 11.85
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 29.34 29.37 29.37 29.38 29.38
investor education and pr... 2.61 2.67 2.65 - 2.72
llp 0.49 0.64 0.62 0.63 0.49
suresh kumar agarwal 1.32 1.32 1.32 1.32 1.32
investor education and pr... - - - 2.73 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Caplin Point Lab - Quaterly Results16 May 2024, 1:55PM Caplin Point Lab - Quaterly Results16 May 2024, 1:55PM Caplin Point Lab - Quaterly Results16 May 2024, 1:55PM Caplin Point gets Colombia's INVIMA approval for Softgel Capsules division6 May 2024, 11:40AM Caplin Point Laboratories informs about press release16 Apr 2024, 2:49PM Caplin Point Laboratories’ arm gets final approval from USFDA for Ofloxacin Ophthalmic Solution16 Apr 2024, 12:30PM Caplin Point Laboratories informs about press release 28 Mar 2024, 12:37PM Caplin Point Laboratories’ arm gets USFDA approval for Ketorolac tromethamine Ophthalmic Solution28 Mar 2024, 11:12AM Caplin Point Laboratories informs about press release27 Mar 2024, 2:58PM Caplin Point Laboratories’ arm completes new Oncology facility in Kakkalur27 Mar 2024, 11:30AM Caplin Point Laboratories informs about loss of share certificate 27 Feb 2024, 2:31PM Caplin Point Laboratories informs about details of loss of certificate 19 Feb 2024, 2:48PM Caplin Point Lab - Quaterly Results9 Feb 2024, 12:46PM Caplin Point Lab - Quaterly Results9 Feb 2024, 12:46PM Caplin Point Lab - Quaterly Results9 Feb 2024, 12:46PM Caplin Point along with arms to invest Rs 700 crore in Tamil Nadu 9 Jan 2024, 11:11AM Caplin Point Laboratories’ arm gets USFDA’s final approval for Ofloxacin Otic Solution8 Jan 2024, 12:41PM Caplin Point Laboratories informs about earnings call transcript18 Nov 2023, 2:51PM Caplin Point Lab - Quaterly Results9 Nov 2023, 12:43PM Caplin Point Lab - Quaterly Results9 Nov 2023, 12:43PM Caplin Point Lab - Quaterly Results9 Nov 2023, 12:43PM Caplin Point Laboratories informs about conference call3 Nov 2023, 1:12PM Caplin Point Laboratories informs about re-appointment of independent director21 Sep 2023, 2:21PM Caplin Point Laboratories informs about appointment of statutory auditors21 Sep 2023, 2:19PM Caplin Point Laboratories’ arm gets USFDA’s final approval for Norepinephrine Bitartrate Injection20 Sep 2023, 2:12PM Caplin Point Laboratories informs about press release20 Sep 2023, 11:42AM Caplin Point Laboratories’ arm gets EIR from USFDA for Chennai unit4 Sep 2023, 12:42PM Caplin Point Laboratories listed on Forbes Asia’s ‘200 Best Under a Billion’ for 202311 Aug 2023, 12:39PM Caplin Point Laboratories reports 21% rise in Q1 consolidated net profit7 Aug 2023, 3:12PM Caplin Point Lab - Quaterly Results7 Aug 2023, 1:50PM Caplin Point Lab - Quaterly Results7 Aug 2023, 1:50PM Caplin Point Lab - Quaterly Results7 Aug 2023, 1:50PM Caplin Point Laboratories’ arm gets approval for incorporate wholly owned subsidiary in US3 Aug 2023, 3:12PM Caplin Point Laboratories informs about incorporation of a step down subsidiary3 Aug 2023, 1:24PM Caplin Point Laboratories informs about details of loss of certificate 1 Aug 2023, 4:59PM Caplin Point Laboratories informs about details of loss of certificate 13 Jun 2023, 5:00PM Caplin Point Laboratories informs about press release12 Jun 2023, 5:13PM Caplin Point Laboratories’ arm gets USFDA’s approval for Cisatracurium Besylate Injection12 Jun 2023, 3:18PM USFDA completes inspection at Sterile Injectable site of Caplin Point Laboratories’ arm1 Jun 2023, 11:53AM Caplin Point Laboratories informs about outcome of board meeting27 May 2023, 2:20PM Caplin Point Lab - Quaterly Results27 May 2023, 12:43PM Caplin Point Lab - Quaterly Results27 May 2023, 12:43PM Caplin Point Lab - Quaterly Results27 May 2023, 12:43PM Caplin Point Laboratories informs about press release12 May 2023, 2:55PM Caplin Point Laboratories’ arm gets USFDA’s nod for Ketorolac Tromethamine Injection12 May 2023, 11:57AM Caplin Point to sell Caplin Point Laboratories Colombia SAS to Caplin Point Far East29 Mar 2023, 6:10PM Caplin Point Laboratories’ arm gets USFDA’s nod for Thiamine Hydrochloride Injection8 Mar 2023, 2:47PM Caplin Point Laboratories informs about press release8 Mar 2023, 12:07PM Caplin Point Laboratories informs about press release3 Mar 2023, 3:04PM Caplin Point Laboratories’ arm gets USFDA’s approval for Rocuronium Bromide Injection3 Mar 2023, 12:39PM

Caplin Point Lab Stock Price Analysis and Quick Research Report. Is Caplin Point Lab an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Caplin Point Lab and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Caplin Point Lab cash from the operating activity was Rs 157.1 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Caplin Point Lab has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Caplin Point Lab , the EPS growth was 24.5281420213839 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Caplin Point Lab has OPM of 41.5012958513838 % which is a good sign for profitability.
     
  • ROE: Caplin Point Lab have a healthy ROE of 22.9695941639621 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Caplin Point Lab is Rs 1289.1. One can use valuation calculators of ticker to know if Caplin Point Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Caplin Point Lab

Caplin Point Laboratories Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Welcome to our website and our comprehensive analysis of Caplin Point Laboratories Ltd. for long-term stock investors looking for detailed insights and information about the company's performance and potential. On our website, we provide a wide range of tools and features to empower investors, including pre-built screening tools and premium analysis tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Caplin Point Laboratories Ltd.Share Price Analysis:

Analyzing the historical share prices of Caplin Point Laboratories Ltd. is vital for long-term investors striving to understand the stock's performance over time. By monitoring share prices, investors can identify trends and patterns that may influence their investment decisions. On the ticker website, we provide an accurate and up-to-date analysis of Caplin Point Laboratories Ltd.'s share prices, accompanied by interactive price charts, to assist investors in monitoring the stock's performance and identifying potential entry and exit points. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Caplin Point Laboratories Ltd.Balance Sheet:

Analyzing the balance sheet of Caplin Point Laboratories Ltd. is essential in gauging the company's financial health and stability, evaluating the quality of earnings, and assessing the sustainability of growth for long-term investors. On the ticker website, we provide Caplin Point Laboratories Ltd.'s balance sheet for thorough analysis, enabling investors to make well-informed investment decisions based on the company's financial position.

Caplin Point Laboratories Ltd.Annual Report:

Caplin Point Laboratories Ltd.'s annual report provides detailed insights into the company's performance, strategies, and future outlook. This report includes information about the company's business operations, financials, and corporate governance practices. For long-term investors, reviewing the annual report is highly recommended as it offers valuable insights into the company's growth prospects and helps assess its potential for generating sustainable returns. On ticker website, investors can conveniently access and download the annual reports of Caplin Point Laboratories Ltd. for in-depth analysis.

Caplin Point Laboratories Ltd.Dividend Analysis:

Caplin Point Laboratories Ltd. has consistently rewarded its investors through dividends, making tracking its dividend payments and announcements crucial in understanding the company's financial performance. By analyzing historical dividend payments and announcements of Caplin Point Laboratories Ltd. on our website, investors can monitor the company's dividend-paying track record using our user-friendly interface.

Caplin Point Laboratories Ltd.Quarterly Result Evaluation:

Keeping track of the quarterly results of Caplin Point Laboratories Ltd. is paramount for long-term investors. Quarterly reports offer insights into the company's revenue, earnings, and relevant financial metrics. On our website, investors can easily download quarterly reports of Caplin Point Laboratories Ltd. for thorough analysis. By studying these reports, investors can gain a comprehensive understanding of the company's financial performance over time, enabling better decision-making when it comes to long-term investments.

Caplin Point Laboratories Ltd.Stock Price Analysis:

Analyzing the price movement of Caplin Point Laboratories Ltd.'s stock is a critical tool for long-term investors. Our website provides detailed price charts that assist investors in identifying trends and patterns in the stock's performance. By studying the historical price movements, investors can identify potential entry and exit points. Paired with our pre-built screening tools, investors can make well-informed decisions based on thorough analysis of Caplin Point Laboratories Ltd.'s stock price. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Caplin Point Laboratories Ltd.Price Chart Analysis:

On our website, investors can access interactive price charts that visually represent the historical movement of Caplin Point Laboratories Ltd.'s stock price. These charts enable investors to identify patterns, trends, and potential opportunities based on the stock's performance. By analyzing the price chart, investors can enhance their understanding of the stock's behavior, and couple it with our pre-built screening tools to make informed investment decisions.

Caplin Point Laboratories Ltd.News Coverage

Staying updated on the latest news and developments related to Caplin Point Laboratories Ltd. is crucial for investors. Our website provides regular news updates related to the company, including company announcements, industry trends, and macroeconomic factors that may impact the stock price. By staying informed, investors can make well-informed decisions based on the most current and relevant information available.

Caplin Point Laboratories Ltd.Conference Call Transcripts:

Conference call transcripts provide in-depth insights into the company's management discussions and interactions with analysts during important conference calls. On our website, investors can conveniently download the transcripts of Caplin Point Laboratories Ltd.'s conference calls, providing valuable knowledge about the company's strategic direction, future plans, and management outlook. By studying these transcripts, investors can gain a comprehensive understanding of Caplin Point Laboratories Ltd.'s performance and prospects.

Caplin Point Laboratories Ltd.Investor Presentations:

Caplin Point Laboratories Ltd. conducts investor presentations to provide an overview of its operations, financial performance, and growth prospects. These presentations offer insights into the company's strategies and initiatives, providing a clearer understanding of the company's goals and direction. On our website, investors can access Caplin Point Laboratories Ltd.'s investors presentations, ensuring they stay informed about the company's initiatives, understand its long-term vision, and assess its potential for generating sustainable returns. These presentations can be complemented and analyzed using our premium analysis tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Caplin Point Laboratories Ltd.Promoters

The promoters of Caplin Point Laboratories Ltd. play a critical role in the company's management and decision-making processes. As an investor, understanding the background and track record of the promoters is essential in gauging their contributions to the company's success. On the ticker website, investors can find valuable information about the promoters of Caplin Point Laboratories Ltd., enabling them to assess their contributions to the company and make well-informed decisions based on comprehensive analysis.

Caplin Point Laboratories Ltd.Shareholders

Understanding the major shareholders of Caplin Point Laboratories Ltd. is critical in assessing the company's ownership structure and potential influences on decision-making. Ticker website provides a detailed breakdown of major shareholders, including institutional and retail ownership. This information helps investors gauge the level of ownership concentration in the stock and evaluate potential risks and opportunities associated with the company's ownership dynamics.

Caplin Point Laboratories Limited ROCE

Caplin Point Laboratories Limited's ROCE (Return on Capital Employed) is a financial metric that measures how efficiently a company is using its capital to generate profits. This ratio is an essential indicator of a company's profitability, as it measures how much profit a company is making from the capital it has invested. You can find Caplin Point Laboratories Limited's ROCE data in the financials table or ratio section.

Caplin Point Laboratories Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a financial ratio that evaluates a company's operating performance. It measures the company's earnings before accounting for the effects of interest, taxes, depreciation, and amortization. Caplin Point Laboratories Limited's EBITDA can be found in the financials table or ratio section.

Caplin Point Laboratories Limited DPS

DPS (Dividend Per Share) is a financial metric that shows how much a company is paying its shareholders per share. Dividends are distributed to the shareholders as a portion of a company's profits. Caplin Point Laboratories Limited's DPS can be found in the financials table or ratio section.

Caplin Point Laboratories Limited EPS

EPS (Earnings Per Share) is a financial metric that measures the amount of earnings per share of a company's common stock. It is calculated by dividing a company's net earnings by the total number of shares outstanding. Caplin Point Laboratories Limited's EPS can be found in the financials table or ratio section.

In conclusion, Caplin Point Laboratories Limited's stock analysis page provides key financial metrics necessary for analyzing a company's performance in the stock market. These metrics can help investors make informed decisions about investing in the company.

Read More
X